By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



The John Hancock Tower, 54th Floor
200 Clarendon Street
Boston  Massachusetts  02116  U.S.A.
Phone: 617-425-9200 Fax: 617-425-9201



Company News
Boston's Rhythm Files For $86 Million IPO 8/27/2014 2:52:16 PM
Rhythm Presents Clinical Data That RM-493 Increases Energy Expenditure In Obesity Study 6/23/2014 6:50:50 AM
Rhythm Presents Positive GI Motility Results For Relamorelin (RM-131) In Phase 2 Chronic Constipation Study 5/6/2014 9:49:25 AM
Rhythm Presents Positive Phase 2 Study Results For Ghrelin Prokinetic Relamorelin (RM-131) In Diabetic Gastroparesis 5/6/2014 9:48:22 AM
Rhythm To Present At The Cowen and Company 34th Annual Health Care Conference 3/3/2014 6:43:33 AM
Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant 9/24/2013 10:06:19 AM
Rhythm Awarded $1.35 Million From The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease 9/10/2013 9:24:47 AM
Rhythm Lands $11 Million Tranche to Advance Its Treatment of GI Disorders 7/31/2013 8:35:17 AM
Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 5/20/2013 1:50:18 PM
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 5/20/2013 10:44:34 AM